Molecular Remissions With Anti-Cd22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated With Improved Complete Remission Durations During Phase I And Iii Testing

BLOOD(2018)

引用 1|浏览4
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要